BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bhutani D, Assal A, Mapara MY, Prinzing S, Lentzsch S. Case Report: Carfilzomib-induced Thrombotic Microangiopathy With Complement Activation Treated Successfully With Eculizumab. Clinical Lymphoma Myeloma and Leukemia 2020;20:e155-7. [DOI: 10.1016/j.clml.2020.01.016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Scheggi V, Merilli I, Cesaroni E, Alterini B. Carfilzomib-induced thrombotic microangiopathy. A case report. J Oncol Pharm Pract 2021;:10781552211067433. [PMID: 34904466 DOI: 10.1177/10781552211067433] [Reference Citation Analysis]
2 Jindal N, Jandial A, Jain A, Lad D, Prakash G, Khadwal A, Nada R, Sethi J, Ahluwalia J, Malhotra P. Carfilzomib-induced thrombotic microangiopathy: A case based review. Hematol Oncol Stem Cell Ther 2020:S1658-3876(20)30118-7. [PMID: 32735793 DOI: 10.1016/j.hemonc.2020.07.001] [Reference Citation Analysis]
3 Ball S, Behera TR, Anwer F, Chakraborty R. Risk of kidney toxicity with carfilzomib in multiple myeloma: a meta-analysis of randomized controlled trials. Ann Hematol 2020;99:1265-71. [DOI: 10.1007/s00277-020-04062-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
4 Rassner M, Baur R, Wäsch R, Schiffer M, Schneider J, Mackensen A, Engelhardt M. Two cases of carfilzomib-induced thrombotic microangiopathy successfully treated with Eculizumab in multiple myeloma. BMC Nephrol 2021;22:32. [PMID: 33461512 DOI: 10.1186/s12882-020-02226-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Freyer CW, Bange EM, Skuli S, Hsu M, Lin J, Cuker A, Cohen AD, Garfall A. Carfilzomib-Induced Atypical Hemolytic Uremic Syndrome in a Patient With Heterozygous CFHR3/CFHR1 Deletion Treated With Eculizumab. Clin Lymphoma Myeloma Leuk 2021:S2152-2650(21)00248-2. [PMID: 34366267 DOI: 10.1016/j.clml.2021.06.019] [Reference Citation Analysis]
6 Camilleri M, Cuadrado M, Phillips E, Wilson W, Jenner R, Pang G, Kamora S, Streetly M, Popat R, Bygrave C, Owen R, Cavenagh J, Chapman M, Sive J, Eccersley L, Sheaff M, Benjamin R, Ramasamy K, Cook G, Virchis A, Chavda SJ, Clifton-Hadley L, Scully MA, Yong K. Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study. Br J Haematol 2021;193:750-60. [PMID: 33650100 DOI: 10.1111/bjh.17377] [Reference Citation Analysis]
7 Monteith BE, Venner CP, Reece DE, Kew AK, Lalancette M, Garland JS, Shepherd LE, Pater JL, Hay AE. Drug-induced Thrombotic Microangiopathy with Concurrent Proteasome Inhibitor Use in the Treatment of Multiple Myeloma: A Case Series and Review of the Literature. Clinical Lymphoma Myeloma and Leukemia 2020;20:e791-800. [DOI: 10.1016/j.clml.2020.04.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]